Galera Therapeutics Balance Sheet Health
Financial Health criteria checks 0/6
Galera Therapeutics has a total shareholder equity of $-143.7M and total debt of $151.0M, which brings its debt-to-equity ratio to -105.1%. Its total assets and total liabilities are $10.1M and $153.8M respectively.
Key information
-105.14%
Debt to equity ratio
US$151.05m
Debt
| Interest coverage ratio | n/a |
| Cash | US$8.29m |
| Equity | -US$143.67m |
| Total liabilities | US$153.77m |
| Total assets | US$10.10m |
Recent financial health updates
Recent updates
Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely
Feb 15
Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely
Oct 25Galera Therapeutics appoints chief medical officer
Sep 01Galera down ~8% after phase 1 data for non-small cell lung cancer combination treatment
Jun 29Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky
Jun 15Is Galera Therapeutics Stock A Buy, Sell, Or Hold? Several Catalysts To Watch In 2022
Mar 23Here's Why We're A Bit Worried About Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation
Feb 24Galera Therapeutics: Trial Reversal Did Not Take The Stock Higher
Dec 24Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky
Nov 04Will Galera Therapeutics (NASDAQ:GRTX) Spend Its Cash Wisely?
Aug 05Here's Why We're Watching Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation
Feb 17Financial Position Analysis
Short Term Liabilities: GRTX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: GRTX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: GRTX has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: GRTX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GRTX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: GRTX has less than a year of cash runway if free cash flow continues to grow at historical rates of 6% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/16 21:25 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Galera Therapeutics, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| null null | BTIG |
| Yigal Nochomovitz | Citigroup Inc |